The DOI matches its Crossref record; 148 of the 152 references it cites were found in a registry or an index.
Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
Open accessAbstract
Androgen receptor (AR) signaling exerts an antiestrogenic, growth-inhibitory influence in normal breast tissue, and this role may be sustained in estrogen receptor α (ERα)-positive luminal breast cancers. Conversely, AR signaling may promote growth of a subset of ERα-negative, AR-positive breast cancers with a molecular apocrine phenotype. Understanding the molecular mechanisms whereby androgens can elicit distinct gene expression programs and opposing proliferative responses in these two breast cancer phenotypes is critical to the development of new therapeutic strategies to target the AR in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“androgens and the expression of the AR have demonstrated both positive and negative outcomes in breast cancer as reviewed in (Hickey et al., 2012, McNamara and Sasano, 2015a, McNamara and Sasano, 2016).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Hickey et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M., Brown, G. D., Gojiš, O., Ellis, I. O., Green, A. R., et al. (2012) · Nature · doi:10.1038/nature10730 · Cited by 2,182
Estrogen Carcinogenesis in Breast Cancer
Yager, J. D., & Davidson, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050776 · Cited by 1,890
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889
Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer
Stark, R. (2012) · Lecture notes in computer science · doi:10.1007/978-3-642-29627-7_30 · Cited by 1,403
Sequence and Expression of Human Estrogen Receptor Complementary DNA
Greene, G. L., Gilna, P., Waterfield, M. D., BAKER, A. J., Hort, Y., & Shine, J. (1986) · Science · doi:10.1126/science.3753802 · Cited by 1,311
Cited by
Sorted by citations
Montalto, F. I., & Amicis, F. D. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 515
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y.-C., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 366
Bonnefoi, H. R., Grellety, T., Trédan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P. H., Abadie‐Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Progesterone and Breast Cancer
Trabert, B. L., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz001 · Cited by 273
Metadata
- Authors
- Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D.
- Affiliations
- Hanson Institute (AU)
- University of Cambridge (GB)
- Corresponding author
- Tilley, W. D.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-08-01
- Volume
- 26
- Issue
- 8
- Pages
- 1252-1267
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- PMC
- PMC3404296
- OpenAlex
- W1974738527
- Cited by
- 289
- References
- 152
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 11 · 2022: 15 · 2021: 40 · 2020: 16 · 2019: 19 · 2018: 27 · 2017: 18 · 2016: 29 · 2015: 22 · 2014: 30 · 2013: 24 · 2012: 1
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH-11-1-, W81XWH)
- European Molecular Biology Organization
- Cancer Research UK
- University of Cambridge
- National Breast Cancer Foundation
- Medical Research Council
- National Health and Medical Research Council (1008349)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- androgen receptor, breast cancer, estrogen receptor alpha, luminal breast cancer, apocrine breast cancer, tumor suppressor, oncogenes, androgen signaling, transcriptional programs, therapeutic targeting
- MeSH terms
- Androgens, Animals, Breast Neoplasms, Female, Growth Inhibitors, Humans, Oncogenes, Receptors, Androgen, Signal Transduction, Genes, Tumor Suppressor, Mammary Glands, Human, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
